(-0.02%) 5 477.50 points
(-0.02%) 38 810 points
(0.01%) 19 923 points
(0.26%) $80.54
(1.15%) $2.82
(0.12%) $2 331.70
(-0.38%) $29.28
(-0.09%) $970.00
(0.02%) $0.932
(-0.12%) $10.64
(0.07%) $0.788
(-1.86%) $86.81
Live Chart Being Loaded With Signals
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease...
Stats | |
---|---|
Šios dienos apimtis | 432 384 |
Vidutinė apimtis | 796 798 |
Rinkos kapitalizacija | 953.77M |
EPS | $0.580 ( Q1 | 2024-05-10 ) |
Kita pelno data | ( $-0.440 ) 2024-08-01 |
Last Dividend | $5.25 ( 2012-12-13 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-9.16 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0380 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-20 | Barbier Remi | Buy | 50 000 | Stock Option (Right to Buy) |
2024-05-20 | Schoen Eric | Buy | 25 000 | Stock Option (Right to Buy) |
2024-05-20 | Cook Robert Christopher | Buy | 10 000 | Stock Option (Right to Buy) |
2024-05-20 | Kupiec James William | Buy | 10 000 | Stock Option (Right to Buy) |
2024-05-16 | Robertson Sanford | Sell | 5 000 | Common Stock |
INSIDER POWER |
---|
74.81 |
Last 93 transactions |
Buy: 2 627 968 | Sell: 532 470 |
Tūris Koreliacija
Cassava Sciences Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Cassava Sciences Inc Koreliacija - Valiuta/Žaliavos
Cassava Sciences Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-1.53M (0.00 %) |
EPS: | $-2.32 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-1.53M (0.00 %) |
EPS: | $-2.32 |
FY | 2022 |
Pajamos: | $-1 800.00 |
Bruto pelnas: | $-1.30M (72 377.78 %) |
EPS: | $-1.800 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.820 |
Financial Reports:
No articles found.
Cassava Sciences Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $14.00 | 2010-12-13 |
Last Dividend | $5.25 | 2012-12-13 |
Next Dividend | $0 | N/A |
Payout Date | 2012-12-24 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $19.25 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.22 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2010 | $14.00 | 37.20% |
2011 | $0 | 0.00% |
2012 | $5.25 | 19.20% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
13 Dec 2012 | $5.25 | 08 Dec 2012 | 17 Dec 2012 | 24 Dec 2012 |
13 Dec 2010 | $14.00 | 25 Oct 2010 | 01 Dec 2010 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -20.40 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.308 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.348 | 1.500 | -4.98 | -7.47 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.738 | 0.800 | 6.31 | 5.05 | [1 - 3] |
quickRatioTTM | 1.623 | 0.800 | 5.16 | 4.13 | [0.8 - 2.5] |
cashRatioTTM | 1.610 | 1.500 | 2.17 | 3.25 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | -37.76 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -2.04 | 2.00 | -0.681 | -1.363 | [0 - 30] |
freeCashFlowPerShareTTM | -2.05 | 2.00 | -1.023 | -2.05 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.382 | 1.000 | 6.96 | 6.96 | [0.2 - 0.8] |
operatingProfitMarginTTM | -42.33 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.0151 | 0.800 | -3.23 | -2.59 | [0.5 - 2] |
Total Score | -3.92 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -16.89 | 1.000 | -1.807 | 0 | [1 - 100] |
returnOnEquityTTM | -0.348 | 2.50 | -3.20 | -7.47 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.05 | 2.00 | -0.682 | -2.05 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -2.04 | 2.00 | -0.681 | -1.363 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 3.04 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -37.43 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.253 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cassava Sciences Inc
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.